Effect of Valsartan on Pharmacokinetics and Pharmacodynamics of Gliclazide in Diabetic rats

Background: Diabetes mellitus and hypertension are the most common coexisting complications across the world.For the effective treatment of these types of patients, the treatment regimen should contain antidiabetic agent like gliclazide and antihypertensive agents like valsartan.In view of this combination, in the present study, we have evaluated the effect of valsartan on pharmacokinetics and pharmacodynamics of gliclazide in rats with diabetes.Materials and Methods: Alloxan with a dose of 120 mg kgG 1 was used to induce the diabetes in rats, then the rats were treated with test drugs i.e., gliclazide (7.2 mg kgG 1 ) and valsartan (37 mg kgG 1 ) at single and multiple doses, by grouping rats as diabetic control, gliclazide alone, gliclazide+valsartan in combination and half therapeutic dose of gliclazide+full dose of valsartan.The blood samples were collected at different intervals and evaluated for pharmacokinetic and pharmacodynamic parameters using blood plasma samples.Results: The pharmacodynamic results from combination of gliclazide+valsartan showed significant difference in blood glucose reduction when compared to gliclazide alone.However, half therapeutic dose of gliclazide+full valsartan dose showed blood glucose reduction as almost equal to gliclazide alone.The pharmacokinetic results showed increased gliclazide plasma concentrations when used in combination with valsartan, when compared to gliclazide+valsaratn with gliclazide alone.Drug interaction was observed between the said drugs.The half dosed gliclazide with valsartan can have significant application for diabetic patients having hypertension, when compared to gliclazide+valsartan. Conclusion: It is showed that combination of gliclazide and valsartan treatment has shown influence on the pharmacokinetics of gliclazide like metabolism/distribution/excretion and shown significant difference in controlling blood glucose.The dosage adjustment of gliclazide is suggestable in patients receiving gliclazide and valsartan.